Liver Disease and Liver Transplantation

Effects of Octaplas and FFP in the management of coagulopathy in liver disease and liver transplantation1,2

  • Prospective, single-blind, randomized study was designed to investigate the safety and efficacy of Octaplas compared with standard FFP in adult patients with coagulopathies due to liver disease or liver transplantation
  • Study was not powered to detect a difference in efficacy
STUDY OBJECTIVES: ASSESS EFFICACY AND TOLERABILITY OF OCTAPLAS
IN CORRECTING THE COAGULOPATHY ASSOCIATED WITH LT AND LD
OctaplasFFP
N (Male/Female)LT: 12 (5/7)
LD: 13 (10/3)
LT: 13 (7/6)
LD: 11 (8/3)
Median age (range)LT: 47 years (20-66)
LD: 50 years (30-69)
LT: 51 years (23-67)
LD: 52 years (26-66)
Median dosage (range)LT: 44 mL/kg (25-104)
LD: 12 mL/kg (11-15)
LT: 44 mL/kg (7-98)
LD: 13 mL/kg (11-17) Conclusions

LT = Liver Transplant, LD = Liver Disease.

Conclusions

  • Similar correction of increased international normalized ratio (INR) and prolonged aPTT values achieved by 24 hours post-treatment
  • Similar number of blood components transfused with both Octaplas and FFP
  • No viral transmission or infections reported. No febrile reactions observed. One patient had a mild reaction to Octaplas (nausea and pruritus)
icon-clip-board Created with Sketch.

Octaplas is approved for plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP).

Read More
References:
  1. Williamson LM, Llewelyn NC, Fisher JP, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999; 39:1227-1234.
  2. Freeman, JW, Williamson LM, Llewelyn C, et al. A randomized trial of solvent/detergent and standard fresh-frozen plasma in the treatment of the coagulopathy seen during orthotopic liver transplantation. Vox Sang 1998; 74(suppl 1):225- 229.